ArticleJournal of pain research2025
A Real-World Study of Cetylated Fatty Acids Food Supplement Administration in Italian Adults for Sub-Acute or Chronic Musculoskeletal Pain.
Article in Journal of pain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This real-world observational study was conducted to evaluate decrease in pain after 30-day administration of a new oral cetylated fatty acids (CFA) food supplement, assess if decreased pain resulted in a lower consumption of oral non-steroidal anti-inflammatory drugs (NSAIDs), and improvement in related gastric side effects. It was the first study of this food supplement in a real-world setting. Patients and Methods: A hundred and twenty Italian primary care physicians recruited 562 patients who were prescribed oral CFA. Patients completed the Brief Pain Inventory (BPI) questionnaire at baseline and after 30 days of dosing. Their CFA intake adherence and use of NSAIDs were recorded. All analyses were done using R statistical software; p-value ≤ 0.005 was considered statistically significant. Results: We analyzed data of 196 males and 366 females aged in an average 49.2 years. After 30 days of CFA intake, we observed a statistically significant reduction (38.84%) in the overall pain score, 44.53% reduction in the interference score in daily activities, relief from pain within the previous 24 hours 47.16 (± 11.44%) at baseline and 62.14 (± 27.93%) after 30 days, and progressive reduction in NSAID intake frequency and total dose over time. More than half of participants (55.2%) reported improvement in gastric side effects typically associated with NSAID use. Conclusion: Data analyses indicated that using the new oral CFA food supplement decreased pain, which helped improve the quality of life, better perform daily activities (interference reduced by 44.5%), and reduce painkiller consumption by 19.7% in terms of both dose and frequency. Half of participants (55.2%) rated NSAID-related hyperchlorhydria and heartburn as improved. Although placebo effect might have contributed, the results suggest that CFA may have a positive effect in patients with sub-acute and chronic musculoskeletal pain and can enhance therapies typically used in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.